NASDAQ:ALLR

Allarity Therapeutics Stock News

Healthcare > Biotechnology

Buy ALLR

*Your capital is at risk

$1.58

-0.110 (-6.51%)

At Close: Jun 03, 2026

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

10:40am, Wednesday, 03'rd Jun 2026

Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

04:30pm, Friday, 15'th May 2026

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer - Allarity has received a Notice of Allowance for new i

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

08:45am, Friday, 08'th May 2026

TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopar

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

08:00am, Tuesday, 05'th May 2026

Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA approv

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

08:00am, Monday, 27'th Apr 2026

TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing steno

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

08:00am, Tuesday, 31'st Mar 2026

Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, en

Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday

02:14am, Monday, 23'rd Mar 2026

Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) is expected to be posting its results before the market opens on Monday, March 30th. Analysts expect Allarity Therapeutics to post earnings of ($

Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Drops By 20.7%

01:41am, Sunday, 15'th Mar 2026

Allarity Therapeutics, Inc. (NASDAQ: ALLR - Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

08:00am, Friday, 06'th Mar 2026

Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Str

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

08:15am, Wednesday, 18'th Feb 2026

Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung Cancer Trial is fully funded by the U.S. Department of Veterans Affairs and is open for enro

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

08:00am, Tuesday, 03'rd Feb 2026

This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by